I’d buy this growing FTSE 100 stock in this market weakness

This FTSE 100 (INDEXFTSE: UKX) firm is executing its growth strategy well in a market with a tailwind.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When I think of the FTSE 100, Rentokil Initial (LSE: RTO) isn’t the first name I tend to remember, but maybe it should be. The company has been performing well over the past few years and the directors are focused on driving strong growth in a robust and expanding market.

I’m impressed by the firm’s record of growing its revenue, earnings and operating cash flow. Over six years, the dividend has risen more than 100%, which I think is a good litmus test of how effective the firm’s growth strategy is as it expands around the world. Roughly 90% of revenue comes from outside the UK with the firm operating in North America, Europe, Asia and the Pacific region, as well as in Britain.

Consolidating a fragmented industry

The core driver of growth is the pest control operation, and the company sees itself as a consolidator in the sector as it thrusts into new territories across the globe. The industry is fragmented, according to the directors, which gives the firm the opportunity to grow by acquiring smaller businesses in areas that offer good growth potential. However, the company also enjoys leading positions in the hygiene services and interior landscaping sectors and states that its business model for profitable growth focuses on “compounding revenue, profit and cash growth through organic growth and M&A (mergers and acquisitions).” 

Today’s third-quarter trading update reveals that continuing revenue at constant currency exchange rates rose almost 12% compared to the equivalent period last year. Just over 4% came from organic growth and the rest from acquisitions. I don’t think I’ve come across a FTSE 100 firm that is as focused on its acquisition programme as Rentokil Initial appears to be. The company acquired 16 new bolt-on businesses in the period, 14 in its Pest Control division, one in the Hygiene division and one in Ambius, its interior landscaping division. Most of the takeovers were in emerging and growth markets.

A strong pipeline

To put the acquisition programme in perspective, the combined annualised revenues of all of the businesses acquired so far in 2018 in the year before Rentokil Initial bought them comes to just over £156m.  That compares to Rentokil Initial’s 2017 turnover of a little over £2.4bn, so the strategy doesn’t expose the firm to big risks. The purchases are small businesses, typically the best-run of several competing firms in an attractive market. Rentokil swoops in, makes an offer, and after it has been accepted applies all its know-how to expand from its initial toe-hold in the new market, which is typically in a fast-growing city somewhere in the world.

The company said in the report that “the M&A pipeline going into Q4 and 2019 remains strong.” And chief executive Andy Ransome said the company is “on track to meet expectations for the full year.”  City analysts following the firm have pencilled in a rise of around 5% in earnings this year and 11% in 2019, so we can expect more steady progress ahead. The shares are not cheap. Today’s share price throws up a forward price-to-earnings ratio close to 22 for 2019, but the business is executing its growth strategy well in a market with a tailwind. I think it deserves its rating and is a good candidate for a long-term hold in my portfolio.  

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »